pfizer-biontech vaccination series Search Results


mrna covid-19 vaccination series  (BioNTech)
90
BioNTech mrna covid-19 vaccination series
Mrna Covid 19 Vaccination Series, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc08893338-109-12-17?v=BioNTech
Average 90 stars, based on 1 article reviews
mrna covid-19 vaccination series - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
mrna-based covid-19 vaccine corminaty  (BioNTech)
90
BioNTech mrna-based covid-19 vaccine corminaty
Mrna Based Covid 19 Vaccine Corminaty, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc11485980-58-19-21?v=BioNTech
Average 90 stars, based on 1 article reviews
mrna-based covid-19 vaccine corminaty - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
series vaccine type  (Janssen)
86
Janssen series vaccine type
Series Vaccine Type, supplied by Janssen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/pm41698311-132-44-60?v=Janssen
Average 86 stars, based on 1 article reviews
series vaccine type - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
monovalent vaccines  (Moderna)
86
Moderna monovalent vaccines
Monovalent Vaccines, supplied by Moderna, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/pm40931721-97-10-12?v=Moderna
Average 86 stars, based on 1 article reviews
monovalent vaccines - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
pfizer-biontech vaccine  (BioNTech)
90
BioNTech pfizer-biontech vaccine
Pfizer Biontech Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc09633262-135-27-27?v=BioNTech
Average 90 stars, based on 1 article reviews
pfizer-biontech vaccine - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
mrna vaccinations  (BioNTech)
90
BioNTech mrna vaccinations
Baseline characteristics, post-PS matching, for mRNA + Ad26.COV2.S vs. primary series.
Mrna Vaccinations, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc11861575-170-12-21?v=BioNTech
Average 90 stars, based on 1 article reviews
mrna vaccinations - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
covid 19 vaccine series  (Johnson & Johnson)
86
Johnson & Johnson covid 19 vaccine series
Baseline characteristics, post-PS matching, for mRNA + Ad26.COV2.S vs. primary series.
Covid 19 Vaccine Series, supplied by Johnson & Johnson, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/10__24839_slash_2325___7342__jn29__2__129-1854-40-58?v=Johnson+%26+Johnson
Average 86 stars, based on 1 article reviews
covid 19 vaccine series - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
btn162b2  (BioNTech)
90
BioNTech btn162b2
Baseline characteristics, post-PS matching, for mRNA + Ad26.COV2.S vs. primary series.
Btn162b2, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/pm36184797-43-18-20?v=BioNTech
Average 90 stars, based on 1 article reviews
btn162b2 - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
covid-19 vaccination series  (BioNTech)
90
BioNTech covid-19 vaccination series
Baseline characteristics, post-PS matching, for mRNA + Ad26.COV2.S vs. primary series.
Covid 19 Vaccination Series, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc09262658-30-3-3?v=BioNTech
Average 90 stars, based on 1 article reviews
covid-19 vaccination series - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
covid-19 vaccine  (BioNTech)
90
BioNTech covid-19 vaccine
Branch retinal artery occlusion (BRAO) after <t>COVID-19</t> vaccinations. A fundus photograph of the right eye of case 1 shows superotemporal BRAO.
Covid 19 Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc08980294-73-12-12?v=BioNTech
Average 90 stars, based on 1 article reviews
covid-19 vaccine - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Baseline characteristics, post-PS matching, for mRNA + Ad26.COV2.S vs. primary series.

Journal: Vaccines

Article Title: Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States

doi: 10.3390/vaccines13020166

Figure Lengend Snippet: Baseline characteristics, post-PS matching, for mRNA + Ad26.COV2.S vs. primary series.

Article Snippet: Adults aged 18 years or older with evidence of a COVID-19 primary series vaccination (two mRNA vaccinations from the same manufacturer [Pfizer-BioNTech or Moderna] or one Ad26.COV2.S vaccination) administered between 1 January 2021 and 6 July 2022 and with at least 365 days of medical and pharmacy pre-index enrollment were eligible for the study cohorts ( ).

Techniques: Infection

Baseline characteristics, post-PS matching, for Ad26.COV2.S + Ad26.COV2.S vs. primary series.

Journal: Vaccines

Article Title: Effectiveness of Heterologous and Homologous Ad26.COV2.S Vaccine Boosting in Preventing COVID-19-Related Outcomes Among Individuals with a Completed Primary Vaccination Series in the United States

doi: 10.3390/vaccines13020166

Figure Lengend Snippet: Baseline characteristics, post-PS matching, for Ad26.COV2.S + Ad26.COV2.S vs. primary series.

Article Snippet: Adults aged 18 years or older with evidence of a COVID-19 primary series vaccination (two mRNA vaccinations from the same manufacturer [Pfizer-BioNTech or Moderna] or one Ad26.COV2.S vaccination) administered between 1 January 2021 and 6 July 2022 and with at least 365 days of medical and pharmacy pre-index enrollment were eligible for the study cohorts ( ).

Techniques: Infection

Branch retinal artery occlusion (BRAO) after COVID-19 vaccinations. A fundus photograph of the right eye of case 1 shows superotemporal BRAO.

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Branch Retinal Artery Occlusions, Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy After COVID-19 Vaccinations

doi: 10.2147/OPTH.S357359

Figure Lengend Snippet: Branch retinal artery occlusion (BRAO) after COVID-19 vaccinations. A fundus photograph of the right eye of case 1 shows superotemporal BRAO.

Article Snippet: Although BRAO/PAMM/AMN in the current case series occurred after administration of the Pfizer-BioNTech COVID-19 vaccine, a definite causal relationship between BRAO/PAMM/AMN and COVID-19 vaccinations could not be established.

Techniques:

Branch retinal artery occlusion (BRAO) after COVID-19 vaccinations. A fundus photograph of the left eye of case 3 shows superotemporal BRAO.

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Branch Retinal Artery Occlusions, Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy After COVID-19 Vaccinations

doi: 10.2147/OPTH.S357359

Figure Lengend Snippet: Branch retinal artery occlusion (BRAO) after COVID-19 vaccinations. A fundus photograph of the left eye of case 3 shows superotemporal BRAO.

Article Snippet: Although BRAO/PAMM/AMN in the current case series occurred after administration of the Pfizer-BioNTech COVID-19 vaccine, a definite causal relationship between BRAO/PAMM/AMN and COVID-19 vaccinations could not be established.

Techniques:

Paracentral acute middle maculopathy (PAMM) after COVID-19 vaccinations. ( A ) A fundus photograph of the left eye of case 5 shows inferonasal parafoveal retinal whitening (arrow) consistent with PAMM. ( B ) A horizontal optical coherence tomography image of the left eye of case 5 demonstrates parafoveal hyperreflective band at the inner nuclear layer (between the arrows) consistent with PAMM corresponding to the area of retinal whitening seen in the fundus photograph.

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Branch Retinal Artery Occlusions, Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy After COVID-19 Vaccinations

doi: 10.2147/OPTH.S357359

Figure Lengend Snippet: Paracentral acute middle maculopathy (PAMM) after COVID-19 vaccinations. ( A ) A fundus photograph of the left eye of case 5 shows inferonasal parafoveal retinal whitening (arrow) consistent with PAMM. ( B ) A horizontal optical coherence tomography image of the left eye of case 5 demonstrates parafoveal hyperreflective band at the inner nuclear layer (between the arrows) consistent with PAMM corresponding to the area of retinal whitening seen in the fundus photograph.

Article Snippet: Although BRAO/PAMM/AMN in the current case series occurred after administration of the Pfizer-BioNTech COVID-19 vaccine, a definite causal relationship between BRAO/PAMM/AMN and COVID-19 vaccinations could not be established.

Techniques: Tomography

Acute macular neuroretinopathy (AMN) after COVID-19 vaccinations. ( A and B ) En face optical coherence tomography angiography images of the superficial capillary plexus ( A ) and deep capillary plexus ( B ) of the left eye of case 6. ( C ) A horizontal optical coherence tomography image with angiographic flow (shown in red) of the left eye of case 6 shows possible flow deficits in the deep capillary plexus and hyperreflective lesions affecting the outer plexiform and outer nuclear layers with disruption of the ellipsoid zone (arrow) consistent with AMN.

Journal: Clinical Ophthalmology (Auckland, N.Z.)

Article Title: Branch Retinal Artery Occlusions, Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy After COVID-19 Vaccinations

doi: 10.2147/OPTH.S357359

Figure Lengend Snippet: Acute macular neuroretinopathy (AMN) after COVID-19 vaccinations. ( A and B ) En face optical coherence tomography angiography images of the superficial capillary plexus ( A ) and deep capillary plexus ( B ) of the left eye of case 6. ( C ) A horizontal optical coherence tomography image with angiographic flow (shown in red) of the left eye of case 6 shows possible flow deficits in the deep capillary plexus and hyperreflective lesions affecting the outer plexiform and outer nuclear layers with disruption of the ellipsoid zone (arrow) consistent with AMN.

Article Snippet: Although BRAO/PAMM/AMN in the current case series occurred after administration of the Pfizer-BioNTech COVID-19 vaccine, a definite causal relationship between BRAO/PAMM/AMN and COVID-19 vaccinations could not be established.

Techniques: Tomography